ICN Pharmaceuticals to Announce First Quarter 2001 Earnings On Thursday, May 3

Apr 25, 2001, 01:00 ET from ICN Pharmaceuticals, Inc.

    COSTA MESA, Calif., April 25 /PRNewswire/ -- ICN Pharmaceuticals, Inc.
 (NYSE:   ICN) announced today that it will host a conference call and webcast on
 Thursday, May 3, 2001 at 10:00 a.m. EST (7:00 a.m. PST) to discuss its
 earnings results for the first quarter of 2001.  The dial-in-number to
 participate live on this call is (719) 457-2624, confirmation code 601745.  A
 replay will be available approximately two hours following conclusion of the
 conference call through May 8, 2001, and can be accessed by dialing
 (719) 457-0820.
     To access the webcast, go to ICN's corporate website at www.icnpharm.com
 and click on the Investor Relations button.
     ICN is a worldwide manufacturer, marketer and distributor of a broad range
 of prescription and non-prescription pharmaceuticals, including
 anti-infectives, anti-virals, and anti-cancer drugs, under the ICN brand name.
     ICN stockholders are strongly advised to read the proxy statement relating
 to ICN's 2001 annual meeting of stockholders when it becomes available, as it
 will contain important information.  Stockholders will be able to obtain this
 proxy statement, any amendments to the proxy statement and other documents
 filed by ICN with the Securities and Exchange Commission without charge at the
 Internet website maintained by the Securities and Exchange Commission at
 www.sec.gov.  In addition, ICN will mail the proxy statement to each
 stockholder of record on the record date to be established for the
 stockholders meeting.  ICN will also make additional copies of the proxy
 statement and any amendments to the proxy statement available without charge
 to ICN's stockholders.  Please direct your request for the proxy statement to
 Investor Relations, ICN Pharmaceuticals, Inc., 3300 Hyland Avenue, Costa Mesa,
 California 92626, telephone (714) 545-0100, extension 3104.
 
     Participant Information
     In accordance with Rule 14a-12(a)(1)(i) of the Securities Exchange Act of
 1934, as amended, the information concerning persons who may be deemed
 participants is as follows:
     ICN, its executive officers and directors named below may be deemed to be
 participants in the solicitation of proxies for ICN's 2001 annual meeting of
 stockholders.  The number of shares of ICN common stock beneficially owned by
 each of these persons as of March 31, 2001 is listed in parenthesis after his
 or her name.
     Milan Panic, Chairman of the Board of Directors and Chief Executive
 Officer, (2,371,092); Adam Jerney, President and Chief Operating Officer and a
 director, (735,498); Richard A. Meier, Executive Vice President and Chief
 Financial Officer, (76,750); David C. Watt, Executive Vice President, General
 Counsel and Corporate Secretary, (188,204); John E. Giordani, Executive Vice
 President, (77,356); Bill A. MacDonald, Executive Vice President, Strategic
 Planning (44,250); Jack L. Sholl, Executive Vice President, Corporate Public
 Relations, (138,682); James G. McCoy, Executive Vice President, Corporate
 Human Resources (none); and Johnson Y.N. Lau, Senior Vice President, Research
 and Development, (18,750).
     ICN's directors who are not also executive officers are: Norman Barker,
 Jr. (141,690); Birch E. Bayh, Jr. (97,266); Alan F. Charles (100,478); Stephen
 D. Moses (84,505); Roger Guillemin M.D., Ph.D. (159,681); Jean-Francois Kurz
 (127,716); Thomas H. Lenagh (124,528); Roberts A. Smith Ph.D. (192,162);
 Andrei Kozyrev, Ph.D. (40,625), Kim Campbell, PC, QC (none), Rosemary Tomich
 (none) and Ray Irani (none).  Charles T. Manatt (36,787) is a nominee for
 election to the Board of Directors.
     ICN is also party to employment agreements with its executive officers
 which provide that, upon the occurrence of specific events following a change
 in control of ICN, the executive officers may be entitled to receive
 compensation and other payments.  Additionally, ICN's executive officers have
 options to acquire shares of ICN's common stock, some of which are unvested as
 of the date hereof.  These options will vest upon a change in control of ICN.
     Any securities of ICN International offered will not be and have not been
 registered under the U.S. Securities Act of 1933, as amended, and may not be
 offered or sold in the United States, absent registration or an applicable
 exemption from registration requirements.
     When available, copies of the preliminary prospectus relating to the
 offering of shares of Class A Common Stock of Ribapharm Inc. may be obtained
 from the offices of UBS Warburg LLC, 299 Park Avenue, New York, New York 10171
 (212) 821-4011.
     A registration statement relating to the shares of Class A common stock of
 Ribapharm Inc. has been filed with the U.S. Securities and Exchange Commission
 but has not yet become effective.  These securities may not be sold nor may
 offers to buy be accepted prior to the time the registration statement becomes
 effective.  This press release shall not constitute an offer to sell or the
 solicitation of an offer to buy, nor shall there be any sale of these
 securities in any state in which such offer, solicitation or sale would be
 unlawful prior to registration or qualification under the securities laws of
 any such state.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X47446114
 
 

SOURCE ICN Pharmaceuticals, Inc.
    COSTA MESA, Calif., April 25 /PRNewswire/ -- ICN Pharmaceuticals, Inc.
 (NYSE:   ICN) announced today that it will host a conference call and webcast on
 Thursday, May 3, 2001 at 10:00 a.m. EST (7:00 a.m. PST) to discuss its
 earnings results for the first quarter of 2001.  The dial-in-number to
 participate live on this call is (719) 457-2624, confirmation code 601745.  A
 replay will be available approximately two hours following conclusion of the
 conference call through May 8, 2001, and can be accessed by dialing
 (719) 457-0820.
     To access the webcast, go to ICN's corporate website at www.icnpharm.com
 and click on the Investor Relations button.
     ICN is a worldwide manufacturer, marketer and distributor of a broad range
 of prescription and non-prescription pharmaceuticals, including
 anti-infectives, anti-virals, and anti-cancer drugs, under the ICN brand name.
     ICN stockholders are strongly advised to read the proxy statement relating
 to ICN's 2001 annual meeting of stockholders when it becomes available, as it
 will contain important information.  Stockholders will be able to obtain this
 proxy statement, any amendments to the proxy statement and other documents
 filed by ICN with the Securities and Exchange Commission without charge at the
 Internet website maintained by the Securities and Exchange Commission at
 www.sec.gov.  In addition, ICN will mail the proxy statement to each
 stockholder of record on the record date to be established for the
 stockholders meeting.  ICN will also make additional copies of the proxy
 statement and any amendments to the proxy statement available without charge
 to ICN's stockholders.  Please direct your request for the proxy statement to
 Investor Relations, ICN Pharmaceuticals, Inc., 3300 Hyland Avenue, Costa Mesa,
 California 92626, telephone (714) 545-0100, extension 3104.
 
     Participant Information
     In accordance with Rule 14a-12(a)(1)(i) of the Securities Exchange Act of
 1934, as amended, the information concerning persons who may be deemed
 participants is as follows:
     ICN, its executive officers and directors named below may be deemed to be
 participants in the solicitation of proxies for ICN's 2001 annual meeting of
 stockholders.  The number of shares of ICN common stock beneficially owned by
 each of these persons as of March 31, 2001 is listed in parenthesis after his
 or her name.
     Milan Panic, Chairman of the Board of Directors and Chief Executive
 Officer, (2,371,092); Adam Jerney, President and Chief Operating Officer and a
 director, (735,498); Richard A. Meier, Executive Vice President and Chief
 Financial Officer, (76,750); David C. Watt, Executive Vice President, General
 Counsel and Corporate Secretary, (188,204); John E. Giordani, Executive Vice
 President, (77,356); Bill A. MacDonald, Executive Vice President, Strategic
 Planning (44,250); Jack L. Sholl, Executive Vice President, Corporate Public
 Relations, (138,682); James G. McCoy, Executive Vice President, Corporate
 Human Resources (none); and Johnson Y.N. Lau, Senior Vice President, Research
 and Development, (18,750).
     ICN's directors who are not also executive officers are: Norman Barker,
 Jr. (141,690); Birch E. Bayh, Jr. (97,266); Alan F. Charles (100,478); Stephen
 D. Moses (84,505); Roger Guillemin M.D., Ph.D. (159,681); Jean-Francois Kurz
 (127,716); Thomas H. Lenagh (124,528); Roberts A. Smith Ph.D. (192,162);
 Andrei Kozyrev, Ph.D. (40,625), Kim Campbell, PC, QC (none), Rosemary Tomich
 (none) and Ray Irani (none).  Charles T. Manatt (36,787) is a nominee for
 election to the Board of Directors.
     ICN is also party to employment agreements with its executive officers
 which provide that, upon the occurrence of specific events following a change
 in control of ICN, the executive officers may be entitled to receive
 compensation and other payments.  Additionally, ICN's executive officers have
 options to acquire shares of ICN's common stock, some of which are unvested as
 of the date hereof.  These options will vest upon a change in control of ICN.
     Any securities of ICN International offered will not be and have not been
 registered under the U.S. Securities Act of 1933, as amended, and may not be
 offered or sold in the United States, absent registration or an applicable
 exemption from registration requirements.
     When available, copies of the preliminary prospectus relating to the
 offering of shares of Class A Common Stock of Ribapharm Inc. may be obtained
 from the offices of UBS Warburg LLC, 299 Park Avenue, New York, New York 10171
 (212) 821-4011.
     A registration statement relating to the shares of Class A common stock of
 Ribapharm Inc. has been filed with the U.S. Securities and Exchange Commission
 but has not yet become effective.  These securities may not be sold nor may
 offers to buy be accepted prior to the time the registration statement becomes
 effective.  This press release shall not constitute an offer to sell or the
 solicitation of an offer to buy, nor shall there be any sale of these
 securities in any state in which such offer, solicitation or sale would be
 unlawful prior to registration or qualification under the securities laws of
 any such state.
 
                     MAKE YOUR OPINION COUNT -  Click Here
                http://tbutton.prnewswire.com/prn/11690X47446114
 
 SOURCE  ICN Pharmaceuticals, Inc.